ClinicalTrials.gg
CompletedNCT04383080Updated Mar 24, 2023

The Effect and Safety of Low-level Laser Therapy in Acute Decompensated Heart Failure Patients.

An interventional study of Acupuncture and Low-level laser therapy in Heart Failure and Acupuncture, sponsored by National Yang Ming Chiao Tung University Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-03-24.

Sponsored by National Yang Ming Chiao Tung University Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 137 studies in Heart Failure with a site in Taiwan — 30 open to participants now, 39 under way, 14 of them phase 3. Heart Failure · Taiwan.

Enrollment
98th of 101
17 · median 177
Started
2020
with 4 others
No phase
49 of 137
11 open now
Registered
64th of 137
by date

Among the 137 studies in Heart Failure with a site in Taiwan, this one is the 98th largest by enrollment of the 101 interventional ones that give a count, is one of 5 that started in 2020, is one of 49 with no phase, and was the 64th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

30 of the 137 studies in Heart Failure with a site in Taiwan are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies in Heart Failure with a site in Taiwan, or all of them as a file.
02

Study summary

The advantages of laser acupuncture are a non-invasive, painless, low risk of infection and high safety. Laser acupuncture as a treatment tool has the following advantages1.Painless, 2. Non-invasive treatment, the subject is highly accepted, the risk of infection and needle stick is low, 3. Very few side effects such as fainting, bleeding, 4. The therapeutic dose is easy to operate, and the instrument output frequency, power and time can be controlled. Through the clinical physiological function test plus the verification and analysis of the quantitative test values, it will be more able to define the new role of laser acupuncture treatment in patients with heart failure from the perspective of Chinese medicine.

Read the detailed description

From the perspective of ancient books, the discussion of heart failure in the etiology and pathogenesis of traditional Chinese medicine was first seen in the "Shu Wen". It is clearly pointed out that "heart qi" is the basic pathogenesis of heart failure. The "qi" and "blood" of Chinese medicine are closely related. The blood line is driven by the gas, the blood is bloody, and the qi deficiency is unable to push the blood to blood. If the qi deficiency, it would lead to blood stasis; There were studies have indicated that traditional acupuncture treatment can increase exercise tolerance and adjust autonomic nerve activity in patients with chronic heart failure, and can reduce their readmission rate and mortality rate in patients with acute heart failure. Studies using laser acupuncture to treat patients with heart failure have also found that they can increase the subject's six-minute walking distance.

03

Conditions studied

  • Heart Failure
  • Acupuncture

Browse trials for

Keywords

  • Low-level Laser
  • Acupuncture therapy
  • Heart Failure
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 20 years of age, with written .
  • :stage II-III.
  • All patients had \<40% caused by dilated or ischemic cardiomyopathy.
  • Acute HF patient presenting with dyspnea related to cardiogenic pulmonary edema.
  • All patients had sinus rhythm, were stable and compensated with individually optimized standard heart failure medication as well as oral anticoagulants for at least 3 months before (including prophylactic defibrillator placement).
  • Systolic blood pressure > 95 mmHg at admission.
  • B-type natriuretic peptide (BNP) > 150 pg/mL or NT-pro BNP > 600 pg/mL.

Exclusion criteria

Exclusion Criteria:

  • Age under 20.
  • Major cardiovascular events and treatments occurred four weeks before hospitalization.
  • Major cardiovascular surgery or treatment will be performed in the next 6 months.
  • Pregnant or expected to pregnancy within a year.
  • Require a heart transplant in 6 months.
  • Uncontrolled atrial or ventricular dysrhythmias.
  • Uncompensated congestive heart failure.
  • Heart failure due to congenital heart disease or obstructive myocardial disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Low-level laser therapy

    Low-level laser irradiation on specific acupuncture points

    Device: Low-level laser therapy

  • Active comparator
    Acupuncture therapy

    Dry needle inserting specific acupuncture points

    Procedure: Acupuncture

Interventions

  • ProcedureAcupuncture

    acupuncture at specific acupuncture points

  • DeviceLow-level laser therapy

    low level laser emission on specific acupuncture points

06

What researchers measure

Primary outcomes

  1. N- terminal pro-brain natriuretic peptide, NT-proBNP

    The change of NT-pro BNP from the date of admission to the end of trial

    Time frame: At the 12th week and 24th week

Secondary outcomes

  1. High sensitivity C-Reactive Protein, hs-CRP Hs-CRP

    The change of NT-pro BNP from the date of admission to the end of trial

    Time frame: At the 12th week and 24th week

Other outcomes

  1. Questionnaires_Instrumental activities of daily living

    (IADL);Scoring from 0 to 4 and higher scores mean better outcome.

    Time frame: At the 4th, 12t, 20th and 24th week

  2. Questionnaires_EuroQol- 5 Dimension

    (EQ-5D);Scoring from 1 to 3 and higher scores mean better outcome.

    Time frame: At the 4th, 12t, 20th and 24th week

  3. Questionnaires_The Minnesota LIVING WITH HEART FAILURE® Questionnaire

    (MLHFQ);Scoring from 0 to 5 and higher scores mean better outcome.

    Time frame: At the 4th, 12t, 20th and 24th week

  4. Questionnaires_Patient Health Questionnaire-9

    (PHQ-9);Scoring from 0 to 3 and higher scores mean worse outcome.

    Time frame: At the 4th, 12t, 20th and 24th week

  5. Questionnaires_Constitution in Chinese Medicine Questionnaire

    (CCMQ);Scoring from 1 to 5 and higher scores correspond to specific body constitution.

    Time frame: At the 4th, 12th, 20th and 24th week

  6. 6 minutes walking test

    (6 minutes walking distance, meters)

    Time frame: At the 4th, 12t, 20th and 24th week

  7. Left ventricular ejection fraction

    (Ejection fraction, %)

    Time frame: At the 24th week

  8. Heart rate variability_SDNN

    (Standard deviation of all normal to normal intervals, ms)

    Time frame: At the 12th and 24th week

  9. Heart rate variability_SDANN index

    (Standard deviation of average normal to normal intervals index, ms)

    Time frame: At the 12th and 24th week

  10. Heart rate variability_ASDNN

    (Average standard deviation of all 5-min R-R intervals, ms)

    Time frame: At the 12th and 24th week

  11. Heart rate variability_rMSSD

    (The square root of the mean of the sum of the squares of differences between adjacent NN intervals, ms)

    Time frame: At the 12th and 24th week

  12. Heart rate variability_LF

    (Low frequency power, normalized unit/ n.u. and ms2)

    Time frame: At the 12th and 24th week

  13. Heart rate variability_HF

    (High frequency power, normalized unit/ n.u. and ms2)

    Time frame: At the 12th and 24th week

  14. Heart rate variability_LF/HF

    (LF/HF Ratio)

    Time frame: At the 12th and 24th week

07

Study locations

1 site
  • National Yang Ming University Hospital
    Ilan, 26042, Taiwan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Dec 2022, 29 months.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's 29 months is close to that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2020
First posted
May 11, 2020
StartActual
Jul 1, 2020
Primary completionActual
Dec 1, 2022
CompletionActual
Dec 17, 2022
Last update
Mar 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04383080
Lead sponsor
National Yang Ming Chiao Tung University Hospital
Responsible party
Sponsor
First posted
May 11, 2020
Start date
Jul 1, 2020
Primary completion
Dec 1, 2022
Completion
Dec 17, 2022
Last update
Mar 24, 2023

Study contacts

Shih Meng Chu, Bachelor
principal investigator · National Yang Ming Chiao Tung University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion